Benzinga

Benzinga

Benzinga

miércoles, septiembre 02

BridgeBio Pharma Inc

BBIONASDAQ
Trade with Public
Trade with Public
$76.57
-0.02-0.03%
al cierre: Sep 1, 5:00 PM EST
$76.20
-0.37-0.48%
After hour: 5:21 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

BridgeBio Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for BridgeBio Pharma (BBIO).

Price Target Range — 9 Quarters

Analyst Consensus — 25 Analysts

23Buy
2Hold
Consensus RatingBuy# Analysts25Avg. Consensus PT$91Upside to Avg. PT+20.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026MizuhoSalim SyedPT RaiseOutperform$96→$110
Aug 12, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$102→$107
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $96 to $110.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $102 to $107.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $100 to $111.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved